Warning: The NCBI web site requires JavaScript to function. more...
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants.
Chirico G, Ravasio R, Sbarigia U.
Ital J Pediatr. 2009 Feb 25;35(1):4.
Related citations
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.
Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86. Review.
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
Nuijten MJ, Wittenberg W, Lebmeier M.
Pharmacoeconomics. 2007;25(1):55-71.
[The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, Fitch Warner K.
An Pediatr (Barc). 2006 Oct;65(4):316-24. Spanish.
Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA.
Clin Ther. 2000 Nov;22(11):1357-69.
Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.
Resch B, Gusenleitner W, Nuijten MJ, Lebmeier M, Wittenberg W.
Clin Ther. 2008 Apr;30(4):749-60.
Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.
J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22.
Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria.
Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.
Pediatr Infect Dis J. 2012 Jan;31(1):e1-8.
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.
Pediatrics. 1999 Sep;104(3 Pt 1):419-27.
Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
Neovius K, Buesch K, Sandström K, Neovius M.
Acta Paediatr. 2011 Oct;100(10):1306-14. doi: 10.1111/j.1651-2227.2011.02309.x. Epub 2011 May 13.
Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH.
Eur J Pediatr. 2003 Apr;162(4):237-44. Epub 2003 Feb 6.
Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE, Mahle WT.
Pediatrics. 2004 Dec;114(6):1606-11.
Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW.
Arch Pediatr Adolesc Med. 2006 Oct;160(10):1070-6.
Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL, Daw JR, Coley KC, Rayburg R.
J Manag Care Pharm. 2010 Jan-Feb;16(1):23-31.
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR.
Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54.
Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
Pediatrics. 2004 Dec;114(6):1612-9.
Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review.
Prescott WA Jr, Doloresco F, Brown J, Paladino JA.
Pharmacoeconomics. 2010;28(4):279-93. doi: 10.2165/11531860-000000000-00000. Review.
Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.
Banerji A, Lanctôt KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, Roberts A.
Pediatr Infect Dis J. 2009 Aug;28(8):702-6.
Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
Mitchell I, Tough S, Gillis L, Majaesic C.
Pediatr Pulmonol. 2006 Dec;41(12):1167-74.
Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.
Pediatr Infect Dis J. 2003 Sep;22(9):823-7.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on